Quick links

 

Quick Contact

If you need any further info contact us:
pharmabiotech@sourcebioscience.com
Tel: +44 (0) 115 973 9018
Fax: +44 (0) 115 973 9021

SNP genotyping


Single Nucleotide Polymorphisms are single base-pair changes in a DNA sequence. They can confer susceptibility or resistance to drug therapies and disease, and a number of SNPs are known to affect drug metabolism and clearance of drug from the body. As such, SNPs may cause toxic build up of drugs and aberrant drug reactions. They are therefore important to detect to ensure that the best possible treatment is given to a patient.

TaqMan® SNP genotyping

Using TaqMan technology, Source BioScience has access to over 1.2 million pre-designed TaqMan assays in 15 species.

The TaqMan® platform is suitable for projects of 10s of SNPs and 1000s of Samples.

Roche AmpliChip®

The Roche AmpliChip® platform is the first pharmacogenetic microarray-based test approved for clinical use. The AmpliChip® CYP450 test identifies a patient's genotype for the CYP2D6 and CYP2C19 genes, which are part of the cytochrome P450 system, which can greatly influence drug metabolism. These two genes code for enzymes that metabolise many antidepressants, antipsychotics, and the anti-cancer agent tamoxifen.

The AmpliChip® CYP450 test can help physicians adjust dosing and select drugs by predicting a phenotype based on a genotype so that patient treatment can be individualised to get the best possible therapeutic results. It can also be used to stratify patients in clinical trials.

Why use Source BioScience?

  • Quality: Rapid turnaround and accurate results. All data is sent in strictest confidence to you on CD-ROM, email or web server. We are also GLP, GCP, CPA accredited
  • Pricing: Our high throughput reduces unit labour and capital costs meaning we can offer exceptional value for money. Furthermore, savings are made by bulk purchase of reagents
  • Personal touch: We can also design, validate and genotype user-defined SNPs
  • Commitment to improvement: We are continuously introducing new technologies to reduce costs, shorten timelines and reduce consumables including amounts of your DNA